Several research firms have recently issued reports on AGN. Edgewood Management LLC increased its stake in Allergan by 24.3% in the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company's stock valued at $106,000 after purchasing an additional 370 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Allergan PLC.by 32.2% in the second quarter. Boston Private Wealth LLC now owns 92,663 shares of the company's stock worth $22,525,000 after buying an additional 6,344 shares in the last quarter. Finally, Pacific Center for Financial Services raised its position in Allergan by 1.3% in the 2nd quarter. Ltd. now owns 503,088 shares of the company's stock worth $103,108,000 after buying an additional 492,930 shares in the last quarter.
Institutional investors have recently added to or reduced their stakes in the stock. UBS Group reaffirmed a buy rating and issued a $275.00 price objective on shares of Allergan in a report on Tuesday, September 26th. JP Morgan reinitiated the shares of AGN in report on Thursday, April 7 with "Overweight" rating. Deutsche Bank reissued a buy rating and set a $215.00 target price on shares of Allergan in a report on Tuesday. Vetr cut shares of Allergan from a "buy" rating to a "hold" rating and set a $180.97 target price for the company.in a report on Wednesday. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. The stock has an average rating of "Hold" and a consensus price target of $226.95. The shares were sold at an average price of $173.89, for a total value of $2,053,119.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher J. Coughlin bought 10,000 shares of the company's stock in a transaction on Tuesday, December 5th. The shares were bought at an average price of $163.30 per share, with a total value of $1,633,000.00. The disclosure for this purchase can be found here. The hedge fund run by John Orrico held 21,959 shares of the railroads company at the end of 2017Q3, valued at $2.90M, down from 51,606 at the end of the previous reported quarter. Mitchell Mcleod Pugh And Williams has 3,975 shares. Moreover, Grassi Inv Management has 0.24% invested in Allergan plc (NYSE:AGN) for 6,825 shares. On the stock's most recent trading day, the company's shares ended the regular session at $177.12, which is 31.03% lower than its 52-week high. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40. The firm has a market cap of $86.09 billion, a PE ratio of 6.44 and a beta of 1.07.
Allergan (NYSE:AGN) last issued its quarterly earnings results on Wednesday, November 1st. The company had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. Comparatively, AGN posted earnings of $4.06 per share in the same quarter, a year earlier.
An earnings forecast is an analyst's outlook for a company's future quarterly or annual earnings. The ex-dividend date of this dividend was Thursday, November 16th. Sold All: 2 Reduced: 0 Increased: 1 New Position: 1. With 2.75 million avg volume, 4 days are for Allergan Plc (NYSE:AGN)'s short sellers to cover AGN's short positions.
Allergan announced that its board has approved a stock buyback plan on Monday, September 25th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to purchase up to 2.8% of its shares through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.
TRADEMARK VIOLATION NOTICE: This article was originally posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this article on another domain, it was stolen and republished in violation of United States and worldwide copyright and trademark law. The original version of this article can be read at https://www.truebluetribune.com/2018/01/14/allergan-plc-agn-position-lowered-by-nisa-investment-advisors-llc.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
AGN has been the subject of a number of other reports.